A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplifications
This study tests a new medication called BGB-53038, designed to target specific cancer-causing genetic changes known as KRAS mutations. Researchers want to find the safest and most effective dose of this new drug, both on its own and when combined with other cancer treatments.
Adults with advanced solid tumors that have specific KRAS genetic changes may be able to join, provided they are well enough for daily activities and meet specific medical history requirements.
Participants will receive the study drug, either alone or with other approved cancer therapies, and will be closely monitored through regular check-ups, scans, and possibly tissue samples to see how the treatment works.
This study has locations in the United States, including California, Kansas, and Maryland, but please note that the study status is currently terminated and is no longer accepting new participants.
- 1Tests a new targeted therapy called BGB-53038 for cancers with KRAS mutations.
- 2Evaluates safety and effectiveness both alone and in combination with other drugs.
- 3The study is currently terminated and is not enrolling new patients.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.